tailieunhanh - Báo cáo y học: "Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study. | Respiratory Research BioMed Central Research Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE SPRUCE study Daryl Freeman 1 Angela Lee2 and David Price1 Open Access Address Department of General Practice and Primary Care University of Aberdeen Aberdeen UK and independent Statistician UK Email Daryl Freeman - daryl@ Angela Lee - leeangelal@ David Price - david@ Corresponding author Published 2 July 2007 Received 5 October 2006 Respiratory Research 2007 8 45 doi 1465-9921 -8-45 Accepted 2 July 2007 This article is available from http content 8 1 45 2007 Freeman et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Clinical trials of tiotropium have principally recruited patients from secondary care with more severe chronic obstructive pulmonary disease COPD and typically had included limitation of concomitant medication. In primary care which is the most common setting for COPD management many patients may have milder disease and also may take a broad range of concomitant medication. Methods This randomised placebo-controlled parallel-group 12-week 44-centre study investigated the efficacy trough forced expiratory volume in I second FEV1 response and safety of additional treatment with once-daily tiotropium 18 pg via the HandiHaler in a primary care COPD population tiotropium N 191 FEV1 L predicted placebo N 183 FEV1 L predicted . Secondary endpoints included trough forced vital capacity FVC response weekly use of rescue short-acting P-agonist and exacerbation of COPD complex of respiratory symptoms events of 3 days in duration requiring a change in .